Get started

Financials · TVTX

Travere Therapeutics Inc. (TVTX) financials

For the twelve months ended Sep 30, 2026, Travere Therapeutics Inc. reported $651.03M of revenue and -$121.51M of net income.

Revenue, TTM
$651.03M
Revenue growth, YoY
+49.4%
Net income, TTM
-$121.51M
Net margin
-18.7%
Cash
$123.54M
P/S
7.67
Market cap
$4.99B
Annual revenue$490.73M
FY2016FY2025
Annual net income-$25.55M
FY2016FY2025
Annual free cash flow-$280.69M
FY2016FY2023

TVTX revenue and earnings growth

TVTX revenueQ3 2026$224.56M

Quarter YoY
+36.2%
QoQ
+32.4%
FY YoY
+110.5%
5Y CAGR
+19.9%

TVTX revenue was $224.56M in fiscal Q3 2026 (ended Sep 30, 2026), up 36.2% from a year earlier and up 32.4% from the prior quarter. For the full fiscal 2025 it was $490.73M, up 110.5% from fiscal 2024. Compound annual growth was +19.9% over 5 years. It rose in 7 of the last 9 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.

TVTX net incomeQ3 2026-$52.34M

TVTX net income was -$52.34M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $25.71M a year earlier. For the full fiscal 2025 it was -$25.55M, compared with -$321.55M in fiscal 2024.

TVTX EPSQ3 2026-$0.55

TVTX diluted EPS was -$0.55 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0.28 a year earlier. For the full fiscal 2025 it was -$0.29, compared with -$4.08 in fiscal 2024.

TVTX free cash flowQ3 2025$14.18M

TVTX free cash flow was $14.18M in fiscal Q3 2025 (ended Sep 30, 2025), compared with -$42.51M a year earlier. For the full fiscal 2023 it was -$280.69M, compared with -$186.48M in fiscal 2022.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$490.73M$233.18M$145.24M$109.46M$131.84M$198.32M$175.34M$164.25M$154.94M$133.59M
Cost of revenue$10.34M$7.74M$11.45M$4.42M$3.82M$6.13M$5.23M$5.53M$3.60M$4.55M
Gross profit$480.39M$225.43M$133.79M$105.04M$128.02M$192.19M$170.10M$158.72M$151.33M$129.04M
Research and development$206.01M$217.50M$244.99M$227.33M$201.16M$131.77M$140.96M$123.76M$78.17M$70.82M
Selling, general and admin$337.20M$264.12M$265.54M$197.52M$126.28M$135.80M$128.95M$103.65M$101.33M$91.94M
Operating income-$62.82M-$323.83M-$388.14M-$319.81M-$199.43M-$176.16M-$137.36M-$80.04M-$53.79M-$58.21M
Interest expense$10.75M$11.18M$11.33M$11.01M$19.70M$19.10M$18.80M$9.81M$4.42M$4.73M
Pre-tax income-$49.27M-$320.51M-$376.11M-$331.15M-$216.88M-$188.79M-$146.45M-$101.87M-$58.36M-$57.58M
Income tax$988.0K$120.0K$223.0K$313.0K$409.0K-$19.36M-$21.0K$811.0K$1.37M-$9.68M
Net income-$25.55M-$321.55M-$111.40M-$278.48M-$180.09M-$169.43M-$146.43M-$102.68M-$59.73M-$47.90M
EPS, basic-$0.29-$4.08-$1.50-$4.37-$3.01-$3.56-$3.46-$2.54-$1.54-$1.29
EPS, diluted-$0.29-$4.08-$1.50-$4.37-$3.01-$3.56-$3.46-$2.54-$1.54-$1.29
Diluted shares89.2M78.9M74.3M63.8M59.8M47.5M42.3M40.4M38.8M38.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$93.03M$58.53M$58.18M$61.69M$165.75M$84.77M$62.44M$102.87M$99.39M$41.00M
Receivables$80.13M$27.12M$21.18M$16.65M$15.91M$15.93M$18.05M$12.66M$13.87M$18.51M
Inventory$36.16M$41.86M$9.41M$4.52M$7.31M$7.61M$6.08M$5.62M$5.35M$2.83M
Current assets$437.56M$416.70M$616.77M$486.44M$582.83M$410.41M$429.06M$495.68M$325.81M$332.35M
Goodwill-$800.0K$800.0K$800.0K$900.0K$900.0K$936.0K$936.0K$936.0K$936.0K
Total assets$605.19M$594.13M$788.91M$672.59M$776.63M$607.44M$604.80M$709.16M$520.35M$525.28M
Current liabilities$159.90M$200.75M$177.91M$142.16M$124.09M$92.66M$95.45M$104.62M$85.67M$83.26M
Total liabilities$490.36M$535.05M$588.10M$629.73M$474.52M$396.23M$383.60M$390.91M$227.21M$217.51M
Shareholders' equity$114.83M$59.08M$200.81M$42.85M$302.11M$211.21M$221.20M$318.25M$293.13M$307.77M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$37.78M-$237.47M-$280.02M-$186.29M-$14.79M-$42.74M-$58.21M-$24.96M$7.40M-$3.44M
Capital expenditures--$668.0K$191.0K$5.10M$6.77M$195.0K$727.0K$887.0K$1.43M
Free cash flow---$280.69M-$186.48M-$19.89M-$49.51M-$58.41M-$25.68M$6.52M-$4.87M
Investing cash flow$27.89M$99.33M$55.78M-$32.55M-$137.62M-$61.33M$19.86M-$203.29M$45.60M$10.37M
Financing cash flow-$33.47M$139.42M$218.75M$117.57M$231.68M$127.71M-$2.08M$231.86M$5.45M-$3.85M
Share repurchases---------$0
Stock-based compensation$44.87M$36.91M$44.25M$38.14M$29.57M$23.61M$21.11M$19.77M$26.87M$29.10M
Depreciation and amortization$60.74M$43.55M$38.53M$20.72M$12.75M$24.58M$20.41M$18.67M$17.80M$16.14M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY110.5%60.5%32.7%-17.0%-33.5%13.1%6.8%6.0%16.0%-
Gross margin97.9%96.7%92.1%96.0%97.1%96.9%97.0%96.6%97.7%96.6%
Operating margin-12.8%-138.9%-267.2%-292.2%-151.3%-88.8%-78.3%-48.7%-34.7%-43.6%
Net margin-5.2%-137.9%-76.7%-254.4%-136.6%-85.4%-83.5%-62.5%-38.6%-35.9%
Free cash flow margin---193.3%-170.4%-15.1%-25.0%-33.3%-15.6%4.2%-3.6%
Return on equity-22.2%-544.3%-55.5%-649.9%-59.6%-80.2%-66.2%-32.3%-20.4%-15.6%
Return on assets-4.2%-54.1%-14.1%-41.4%-23.2%-27.9%-24.2%-14.5%-11.5%-9.1%
Current ratio2.742.083.473.424.704.434.504.743.803.99

Source: XBRL data Travere Therapeutics Inc. files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TVTX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TVTX$651.03M+49.4%-$121.51M-18.7%$4.99B
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$675.92B
ABBV$66.01B+10.7%$10.34B15.7%$519.48B
MRK$67.38B+4.9%$2.45B3.6%$364.98B
NVS$54.53B+8.4%$13.98B25.6%$311.52B
AZN$58.74B+8.6%$10.22B17.4%$289.61B
ABT$48.23B+10.0%$4.70B9.7%$191.31B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$180.22B

TVTX FAQ

7 questions
  • What is TVTX revenue?
    Travere Therapeutics Inc. (TVTX) reported $651.03M of revenue for the twelve months ended Sep 30, 2026. That is up 49.4% from the year before. Revenue for fiscal 2025 was $490.73M.
  • Is TVTX profitable?
    No. Travere Therapeutics Inc. reported a net loss of $121.51M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does TVTX have?
    Travere Therapeutics Inc. reported $123.54M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is TVTX revenue growing?
    Travere Therapeutics Inc.'s revenue changed +110.5% in fiscal 2025, to $490.73M. Its compound annual growth rate was +19.9% over 5 years.
  • What is TVTX gross margin?
    Travere Therapeutics Inc.'s gross profit was $641.49M on $651.03M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 98.5%.
  • When did TVTX last report financial results?
    The latest statements here come from Travere Therapeutics Inc.'s 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
  • Where does this TVTX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Travere Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.